The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry

Abstract

Description

Bu çalışma, 13-16 Haziran 2018 tarihlerinde Amsterdan[Hollanda]’da düzenlenen Congress of the European-League-Against-Rheumatism (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.

Keywords

Rheumatology

Citation

Uslu, S. vd. (2018). ''The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry''. Annals of the Rheumatic Diseases, 77(Supplement 2), 329-329.

Collections